Aldeyra Therapeutics Inc. (ALDX)
ALDX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ALDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001341235 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $41.0M cash; operating cash flow -$4.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 60,356,541 (2026-11-03); 60,162,773 a year earlier; 58,822,083 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-03-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $523K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$3.8M | -$4.1M | $41.0M | $0 | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$5.5M | -$4.6M | $45.1M | $0 | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$3.5M | -$5.1M | $65.0M | $15.3M | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | Not filed | -$6.5M | -$5.3M | $70.0M | $15.3M | Needs four quarters | 10-K 2026-02-27 |
| Q3 2025 2025-09-30 | Not filed | -$7.7M | -$7.0M | $59.3M | $15.3M | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$9.8M | -$8.6M | $41.2M | $15.3M | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$9.9M | -$12.5M | $50.4M | $15.3M | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | Not filed | -$15.8M | -$12.0M | $54.5M | $15.3M | Needs four quarters | 10-K 2026-02-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-08-01 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.6% |
| 1 month | -28.4% |
| 3 months | -55.3% |
| Year to date | -87.6% |
| 1 year | -87.2% |
| From 52-week high | -88.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limited | $0.6430 | -5.05% | $40.5M |
| DWTX | Dogwood Therapeutics Inc. | $1.06 | -8.62% | $40.5M |
| GANX | Gain Therapeutics Inc. | $0.9402 | -9.60% | $41.9M |
| ELTX | Elicio Therapeutics Inc. | $1.48 | -1.33% | $41.9M |
| IBO | Impact BioMedical Inc. | $4.91 | -4.47% | $42.4M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier